GEN Exclusives

More »

Research Papers

For full access to this article login to GEN Select now.

ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24- phenotype.

Ying Zhong,Songjie Shen,Yidong Zhou,Feng Mao,Jinghong Guan,Yan Lin,Yali Xu,Qiang Sun

  • Medical Oncology
  • Published in: Volume:31 Issue 3: 2014 March 01
  • Abstract

  • Breast cancer stem cells are thought to be associated with metastasis and poor prognosis, but their clinical importance remains poorly understood. The aim of this study was to investigate whether certain phenotypes of breast cancer stem cells were clinically important factors regarding metastasis. Patients with primary breast cancer (n=121) were included in this study. Breast cancer stem cells were identified by immunohistochemical staining of CD44, CD24, and aldehyde dehydrogenase 1 (ALDH1) in tumor tissues from primary and recurrent or metastatic lesions. CD44+/CD24- cells and ALDH1+ cells were considered breast cancer stem cells. Sixty-five patients had metastatic or recurrent tumors. ALDH1+ tumors were significantly associated with a high rate of metastasis or recurrence (63.1%; P=0.026). Although there was no significant association between the proportion of CD44+/CD24- tumor cells and metastasis rates, a high proportion of CD44+/CD24- tumor cells was a risk factor for metastasis or recurrence (P=0.035). Changes in the proportion of CD44+/CD24- or ALDH1+ tumor cells between primary lesions and recurrent lesions were studied in 27 patients. The proportion of ALDH1+ tumor cells increased significantly (P=0.019) after recurrence, but the proportion of CD44+/CD24- tumor cells did not. Our findings suggest that ALDH1+ and CD44+/CD24- breast cancer stem cells play significant roles in metastasis. The rate of ALDH1+ cells appears to be a better predictive marker of breast cancer metastasis than the CD44+/CD24- phenotype.

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

    • Do not put any letters or characters here if you are not a spy program.

Get GEN Select Access Now


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

GEN Poll

More » Poll Results »

Companion Animal Care

Do you think Americans spend too much on companion animal care?